$NUVB
Nuvation Bio Inc.
XNYS
Why is NUVB down today? It is at $6.30 (-1.02%), and our scanner flagged it 102 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment NUVB spikes, and full due diligence on NUVB — key stats, earnings, dilution and insider activity. Free.
Get free $NUVB alerts the moment volume spikes
Our scanner flagged $NUVB 102 times in the last 30 days. Create a free account to track $NUVB, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $6.30
- Change today
- -1.02%
- Previous close
- $6.37
- 52-week range
- $2.18 – $9.75
- Market cap
- $2.22B
- Institutional own.
- 67.96%
- Total held
- 68.0%
- Tradeable float
- 111.6M 32% of shares · after 68% institutions
- Short interest
- 55.7M ▲ +2% vs prior · as of 2026-07-15
- Short % of float
- 49.9%
- Days to cover
- 8.0d
- Avg daily volume
- 6.4M
- Exchange
- XNYS
- 5m
- 1.7x
- 15m
- 0.9x
- 1h
- 2.1x
- 1D
- 0.2x
Get free NUVB + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $NUVB down today?
NUVB is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 5 unusual-volume and momentum alerts on NUVB today, peaking at 21.7x its normal volume. Fresh from the SEC: Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystNuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateReported Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib)Reported ~85% of the approximatelyReported 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
1 open-market buy1 buys, 3 sells last 3 months (2/15 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Sauvage Philippe Officer | Other | 40K 0.01% of company | added 100% | 54K | $79K at $1.97 | Jul 15, 26 |
Sauvage Philippe Officer | Sold (automatic/other) | -48K 0.01% of company | sold 79% | 13K | $286K at $6.01 | Jun 23, 26 |
Sauvage Philippe Officer | Other | 48K 0.01% of company | added 100% | 60K | $103K at $2.17 | Jun 23, 26 |
Wentworth Kerry Officer | Sold (automatic/other) | -63K 0.02% of company | sold 54% | 53K | $379K at $6.02 | Jun 23, 26 |
Wentworth Kerry Officer | Other | 63K 0.02% of company | added 100% | 116K | $185K at $2.93 | Jun 23, 26 |
Markel Stacy Officer | Sold (automatic/other) | -125K 0.04% of company | sold 79% | 33K | $754K at $6.03 | Jun 23, 26 |
Markel Stacy Officer | Other | 125K 0.04% of company | added 100% | 158K | $218K at $1.74 | Jun 23, 26 |
Mashal Robert Director | Bought (open market) | +25K | added 13% | 225K | $118K at $4.73 | Jun 9, 26 |
Liu Dongfang Officer | Sold (automatic/other) | -50K 0.01% of company | sold 74% | 18K | $251K at $5.02 | Apr 17, 26 |
Liu Dongfang Officer | Other | 50K 0.01% of company | added 100% | 68K | $97K at $1.94 | Apr 17, 26 |
Wentworth Kerry Officer | Sold (automatic/other) | -37K 0.01% of company | sold 41% | 53K | $184K at $5.01 | Apr 17, 26 |
Wentworth Kerry Officer | Other | 37K 0.01% of company | added 69% | 90K | $108K at $2.93 | Apr 17, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringRecent priced share offering — a one-time sale that has already completed (not ongoing). If $NUVB runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$NUVB Sentiment
NeutralBlend of news sentiment, today’s move, and community votes. Not investment advice.
$NUVB Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
NUVB stock FAQ
Why is $NUVB down today?
NUVB is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 5 unusual-volume and momentum alerts on NUVB today, peaking at 21.7x its normal volume. Fresh from the SEC: Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update. A material company disclosure like this is often the real catalyst behind a move of this size.
What is the NUVB stock price today?
NUVB last traded at $6.30, down 1.02% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live NUVB alerts?
The NUVB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged NUVB 102 times in the last 30 days.
What exchange is NUVB on?
NUVB (Nuvation Bio Inc.) trades on XNYS, with a market cap of about $2.22B.
Is NUVB good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge NUVB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.